Literature DB >> 20228010

Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects.

Andrea Rosanoff1.   

Abstract

UNLABELLED: Comprehensive analytical review of 44 human studies in 43 publications of oral Magnesium (Mg) therapy for hypertension (HT) shows Mg supplements may enhance the blood-pressure (BP) lowering effect of anti-hypertensive medications (medications) in Stage 1 HT subjects. 9 studies conducted on subjects treated with medications continuously >/= 6 months (with </= 2-wk washout) resulted in significant decreases in both SBP and DBP with oral Mg supplements as low as 230 mg (10 mmol) per day. Twice this oral Mg dose, i.e. 460 mg/day, was required to significantly lower both SBP and DBP in 18 of 22 studies conducted on Stage 1 HT subjects either treatment-naïve or with their medication use interrupted >/= 4 weeks within 6 months pre-study. Of the 4 remaining studies showing no BP change at these high Mg doses, two had large placebo effect, a third one had significant baseline discrepancies between Mg-test and placebo groups, and the fourth showed a significant decrease in DBP but not SBP. Thirteen studies on normotensive subjects, both treated and untreated with medications, showed no significant BP lowering effect with oral Mg therapy up to 25 mmol/day (607 mg).
CONCLUSIONS: Mg supplements above RDA may be necessary to significantly lower high blood pressure in Stage I HT unless subjects have been continuously treated with anti-HT medications >/= 6 months. Such medication use may lower by half the oral Mg dose needed to significantly decrease high blood pressure. Oral Mg therapy may have no effect in studies with normotensive subjects. Study of oral Mg therapy for severe or complicated hypertension has been neglected. Often the first cardiovascular risk factor to present, high blood pressure may be an early opportunity to correct poor Mg status and its possible complications including cardiovascular disease, respiratory diseases, and type 2 diabetes. Such preventive potential encourages quantification of these findings and testing of these hypotheses with a meta-analysis using categories elucidated by this preliminary study and finally would warrant a call for a prospective study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228010     DOI: 10.1684/mrh.2010.0198

Source DB:  PubMed          Journal:  Magnes Res        ISSN: 0953-1424            Impact factor:   1.115


  10 in total

1.  Perspective: The Case for an Evidence-Based Reference Interval for Serum Magnesium: The Time Has Come.

Authors:  Rebecca B Costello; Ronald J Elin; Andrea Rosanoff; Taylor C Wallace; Fernando Guerrero-Romero; Adela Hruby; Pamela L Lutsey; Forrest H Nielsen; Martha Rodriguez-Moran; Yiqing Song; Linda V Van Horn
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

2.  Short-term Mg deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review.

Authors:  Burton M Altura; Nilank C Shah; Gatha J Shah; Aimin Zhang; Wenyan Li; Tao Zheng; Jose Luis Perez-Albela; Bella T Altura
Journal:  Int J Clin Exp Med       Date:  2014-01-15

3.  Short-term magnesium deficiency upregulates sphingomyelin synthase and p53 in cardiovascular tissues and cells: relevance to the de novo synthesis of ceramide.

Authors:  Burton M Altura; Nilank C Shah; Zhiqiang Li; Xian-Cheng Jiang; Aimin Zhang; Wenyan Li; Tao Zheng; Jose Luis Perez-Albela; Bella T Altura
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-08       Impact factor: 4.733

4.  The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials.

Authors:  Daniel T Dibaba; Pengcheng Xun; Yiqing Song; Andrea Rosanoff; Michael Shechter; Ka He
Journal:  Am J Clin Nutr       Date:  2017-07-19       Impact factor: 7.045

5.  Magnesium deficiency upregulates sphingomyelinases in cardiovascular tissues and cells: cross-talk among proto-oncogenes, Mg(2+), NF-κB and ceramide and their potential relationships to resistant hypertension, atherogenesis and cardiac failure.

Authors:  Burton M Altura; Nilank C Shah; Gatha J Shah; Wenyan Li; Aimin Zhang; Tao Zheng; Zhiqiang Li; Xian-Cheng Jiang; Jose Luis Perez-Albela; Bella T Altura
Journal:  Int J Clin Exp Med       Date:  2013-10-25

Review 6.  The role of magnesium in hypertension and cardiovascular disease.

Authors:  Mark Houston
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-09-26       Impact factor: 3.738

7.  Magnesium in disease.

Authors:  Helmut Geiger; Christoph Wanner
Journal:  Clin Kidney J       Date:  2012-02

8.  Effectively Prescribing Oral Magnesium Therapy for Hypertension: A Categorized Systematic Review of 49 Clinical Trials.

Authors:  Andrea Rosanoff; Rebecca B Costello; Guy H Johnson
Journal:  Nutrients       Date:  2021-01-10       Impact factor: 5.717

9.  Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats.

Authors:  Kyubok Jin; Tae Hee Kim; Yeong Hoon Kim; Yang Wook Kim
Journal:  Korean J Intern Med       Date:  2013-02-27       Impact factor: 2.884

Review 10.  Role of Magnesium Deficiency in Promoting Atherosclerosis, Endothelial Dysfunction, and Arterial Stiffening as Risk Factors for Hypertension.

Authors:  Krasimir Kostov; Lyudmila Halacheva
Journal:  Int J Mol Sci       Date:  2018-06-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.